Latest News of ROIV
Roivant Sciences (ROIV): High-Growth UK Stock with Innovative Drug Development Model
By Yahoo! Finance |
2 weeks ago
Roivant Sciences (NASDAQ:ROIV) is a UK high-growth stock, known for its innovative biopharmaceutical developments. The company recently made a strategic sale of its subsidiary to Organon & Co., boosti...
Roivant Sciences Ltd. (ROIV): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
By Yahoo! Finance |
3 weeks ago
Roivant Sciences Ltd. (NASDAQ:ROIV) is ranked as the top mid-cap stock by hedge funds, showing impressive growth. With a focus on drug development and positive trial results, the company's expansion s...
Is Roivant Sciences Ltd. (ROIV) a Strong Buy Amid Positive Clinical Trials and Strategic Partnerships?
By Yahoo! Finance |
1 month ago
A list of top small company stocks to invest in was recently published, analyzing Roivant Sciences Ltd. against others. With the Fed's interest rate cuts impacting the market, small-cap stocks are see...
-
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
By Yahoo! Finance | 1 month agoThe Federal Reserve's interest rate cut led to market gains, with NASDAQ outperforming. Large-cap tech stocks drove the index's growth, creating opportunities for small and mid-cap stocks. Roivant Sci...
-
Is Roivant Sciences Ltd. (ROIV) the Best Guru Stock To Buy Now?
By Yahoo! Finance | 1 month agoA list of the 10 Best Guru Stocks includes Roivant Sciences Ltd. (NASDAQ:ROIV). Hedge funds focus on stock picking for profits. The GURU ETF combines Buffett's advice with hedge funds' top stocks. Roi...
-
Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion
By MarketWatch | 1 month agoOrganon is acquiring Dermavant Sciences for up to $1.2 billion, expanding its dermatology portfolio with Vtama, a topical therapy for psoriasis. Organon will make an upfront payment of $175 million an...
-
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
By Yahoo! Finance | 1 month agoBayer received $14 million upfront for mosliciguat, a lung-targeted sGC activator. Pulmovant presented promising Phase 1b data at the ERS Congress. The drug showed significant reductions in pulmonary ...
-
Roivant Sciences Shows Market Leadership With Jump To 80 RS Rating
By Investor's Business Daily | 1 month agoLearn how to find the best IPO stocks using a unique rating system based on technical performance. Stocks with an RS Rating over 80 tend to have the biggest price moves. Roivant Sciences is currently ...
-
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance | 2 months agoRoivant released financial results for the first quarter of 2024, with updates on Immunovant's MG trial progress. Enrollment completed, with topline results expected by March 31, 2025. Development of ...